CBF-AML were also excluded from the recent QUAZAR AML-001 study which demonstrated that maintenance with oral azacitidine CC-486 prolongs OS and RFS in patients with AML in first remission after intensive chemotherapy who were not candidates for allogeneic stem cell transplant [45]. Here, CEBPZ is linked to acute myeloid leukemia.